Belpointe Asset Management’s Ventyx Biosciences VTYX Stock Holding History

Belpointe Asset Management’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-76	Closed	-$2.55K	–	3336
2023 Q1	$2.55K	Buy	76 +22	+41%	+$855	﹤0.01%	3242
2022 Q4	$1.77K	Buy	+54	New	+$1.6K	﹤0.01%	3299

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Belpointe Asset Management's VTYX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ventyx Biosciences (VTYX) in Q2 2023, closing a stake of 76 shares — an estimated $2.55K sold.

Belpointe Asset Management first reported a position in VTYX in Q4 2022 and held it in 2 quarters. The position peaked at $2.55K in Q1 2023. 150 funds tracked by Wall St. Rank hold VTYX as of Q2 2023.

Belpointe Asset Management reported no remaining Ventyx Biosciences position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 76 Ventyx Biosciences shares in Q2 2023, an estimated $2.55K.
Belpointe Asset Management first reported a position in Ventyx Biosciences in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Ventyx Biosciences position peaked at $2.55K in Q1 2023.
150 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.